Trydonis

Trydonis is an inhaled triple‑combination product that brings together beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium to support adults with chronic obstructive pulmonary disease (COPD) whose symptoms remain significant despite dual therapy. It is designed for ongoing maintenance to help improve breathing comfort, reduce flare‑ups, and support daily lung function.
Beclometasone dipropionate is a corticosteroid that targets inflammation in the airways. It works by altering the release of substances involved in inflammatory responses, helping reduce swelling and irritation in lung tissues. Formoterol fumarate dihydrate is a long‑acting beta‑2 agonist that relaxes the smooth muscles around the airways, which helps widen the passages and facilitates airflow. Glycopyrronium works as a long‑acting muscarinic antagonist, blocking signals that tighten airway muscles and contribute to bronchoconstriction. The combined actions of these three components offer both anti‑inflammatory effects and sustained bronchodilation through complementary mechanisms.
Used via a portable inhaler device, Trydonis delivers measured doses of each agent and typically involves twice‑daily use to maintain stable activity throughout the day. Regular and proper inhalation technique is key to maximizing the benefits, and users often find that coordinated airway relaxation and reduced inflammation contribute to fewer symptoms like shortness of breath and wheezing.
Responses associated with Trydonis can include oral yeast infections, muscle spasms, dry mouth, and throat irritation, reflecting the combined effects of its components. Good inhaler hygiene, such as rinsing the mouth after use, can help reduce local irritation.
When used as part of a broader pulmonary care plan — including quitting smoking, avoiding triggers, and engaging in respiratory exercises — Trydonis offers a comprehensive triple‑action option for supporting long‑term respiratory health in people with moderate to severe COPD.